POLICY • NEWS • MARKETS
AG POLICY & MARKETS
SPECIAL REPORT
SATURDAY, JULY 18, 2026 | GLYPHOSATE TRADE POLICY
Ruveon Retreats: Bayer’s Glyphosate Unit Pulls China Trade Petitions After Farm-Group Firestorm
Withdrawal of antidumping and countervailing duty petitions on Chinese glyphosate ends a three-week standoff that pitted the only U.S. maker of the herbicide against the very farm groups that defended it at the Supreme Court.
Bayer’s newly formed U.S. glyphosate unit, Ruveon LLC, announced Friday (July 17) that it will withdraw the petitions it filed asking the federal government to open antidumping (AD) and countervailing duty (CVD) investigations into glyphosate imports from China. The reversal came barely three weeks after the petitions landed at the Commerce Department and the U.S. International Trade Commission (ITC) — and after a rare, unified and unusually blunt backlash from commodity groups including the National Corn Growers Association (NCGA), American Soybean Association (ASA) and National Association of Wheat Growers (NAWG).
The petitions, filed June 30 in Monsanto’s name, alleged Chinese producers were selling glyphosate in the U.S. at less than fair value and benefiting from unfair government subsidies. The requested dumping margins were eye-popping: 68.9% to 446.47%. Duties at anywhere near those levels would have sharply raised the cost of generic glyphosate, the workhorse herbicide U.S. row-crop farmers depend on.
THE BACKSTORY: TIMING COULD HARDLY HAVE BEEN WORSE
The filing came just five days after Bayer secured a favorable Supreme Court outcome in its long-running Roundup litigation fight — a case in which roughly a dozen major farm organizations, including the American Farm Bureau Federation, NCGA, ASA and NAWG, filed friend-of-the-court briefs on Bayer’s behalf, warning that an adverse ruling could jeopardize farmers’ access to the product. The whiplash was not lost on farm-group leaders. NCGA President Jed Bower put it bluntly: “We went to bat for them for so long in those court cases,” calling the tariff push “no act of partnership.”
Adding another wrinkle, Bayer stood up Ruveon LLC on July 1 — the day after the petitions were filed — consolidating its entire U.S. glyphosate business (pricing, production, logistics and the Roundup brands) into a distinct St. Louis-based entity led by CEO Alfonso Alba Ordóñez. Bayer described the move as part of its Crop Science division’s five-year framework to restore growth and profitability. Ruveon thus inherited both the petitions and the political firestorm they ignited.
WHY RUVEON BACKED DOWN
Ruveon initially defended the petitions as a response to “predatory trade practices.” But the pressure campaign from its own customer base proved decisive. In announcing the withdrawal, the company said: “Today’s decision reflects our commitment to putting farmers first and meeting their evolving needs, especially during this challenging farm economy.”
KEY POINT Ruveon said it will “continue with our current dynamic pricing approach, based on the price of generic glyphosate products in the market,” while cautioning that pricing remains contingent on production and energy costs.
FARM GROUP REACTION
NCGA President Jed Bower welcomed the reversal: “Input costs are a top concern of growers… Actions like the ones Ruveon planned would have made an already bad situation even worse.”
ASA President Scott Metzger said the group “provided extensive feedback to Ruveon following the filing of the petitions” and that the withdrawal “reflects the value they place on farmer customers.”
NAWG CEO Sam Kieffer coupled his praise with a warning, urging Ruveon to “remember the sharp response they received from farmers” and to “refrain from extreme, upward price swings.”
MARKET CONTEXT
Bayer/Monsanto is the last remaining U.S. glyphosate manufacturer, producing roughly 60% of domestic supply, with glyphosate revenue of about $2.4 billion in 2024. Chinese generics supply much of the remainder and effectively set the price floor. Farm groups pointed to a cautionary precedent: a Texas A&M study estimated that similar duties imposed on phosphate fertilizer imports cost U.S. crop producers roughly $6.9 billion from 2021 through 2025. With net farm income under pressure and input costs stubbornly elevated, growers saw the glyphosate petitions as a direct threat to already-thin margins.
PERSPECTIVE
- Farm groups flexed real muscle — and won fast. Trade-remedy petitions rarely die in three weeks. The speed of Ruveon’s retreat shows how politically untenable it is to ask financially stressed farmers to pay more for their single most-used herbicide, and it demonstrates that commodity groups, acting in concert, can still move a multinational when they speak with one voice. Expect the groups to bank this playbook for future input-cost fights.
- Bayer’s underlying dilemma has not gone away. The petitions were a symptom, not the disease. Bayer faces relentless price competition from low-cost Chinese glyphosate while still carrying the costs of its Roundup legal saga. Withdrawing the petitions removes the political problem but not the economic one: if generic prices keep grinding lower, Bayer must either absorb thinner margins at its U.S. production, seek other forms of relief, or eventually revisit the future of domestic glyphosate manufacturing. Analysts say to watch whether the company pivots to lobbying for broader trade action it doesn’t have to own alone — for example, encouraging the administration to self-initiate an investigation.
- The Ruveon structure is worth watching. Consolidating the U.S. glyphosate business into a standalone entity gives Bayer strategic flexibility — cleaner accounting of the business, a distinct brand to take pricing heat, and, many analysts believe, optionality for a future sale, spinoff or restructuring of the glyphosate franchise. How Ruveon prices this fall and into 2027 will be the first test of its “dynamic pricing” pledge — and Kieffer’s warning suggests farm groups will be watching for any sign the withdrawal is followed by backdoor price increases.
- A withdrawal is not necessarily the end. Petitioners can refile trade cases, and the Commerce Department retains authority to self-initiate AD/CVD investigations. If Chinese glyphosate prices fall further or trade tensions with Beijing escalate, this issue could resurface — next time with the administration, rather than Bayer, holding the pen. Farm groups’ quick mobilization this round means any future effort will face organized, well-rehearsed opposition.
- A larger fault line in farm policy. The episode underscores the tension between trade protection for U.S. input manufacturers and low input costs for producers. From fertilizer to crop protection, that tension is intensifying as more chemical and input production migrates overseas. Policymakers will increasingly be forced to choose between preserving domestic manufacturing capacity and shielding farmers from input-cost inflation — and this fight showed which side of that ledger carries more immediate political weight in farm country.
BOTTOM LINE
BOTTOM LINE Ruveon’s climbdown is a clear near-term win for growers heading into a tight-margin 2026-27 marketing year, sparing them potential glyphosate price spikes. But the structural forces that prompted the petitions — Chinese overcapacity, generic price pressure and the economics of the last U.S. glyphosate plant — remain fully intact. This is a truce, not a peace treaty.
